patient subgroup...
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
anti-inflammatoty and immuno-therapy - versus control - for COVID-19 mild to moderate
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.67 [0.48, 0.93]< 1 0% 6 studies (7/-) 99.1 % some concern not evaluable moderate crucial - death or transfer to ICU 1.07 [0.73, 1.57]< 1 0% 1 study (1/-) 36.6 % NA not evaluable crucial - deaths 0.65 [0.50, 0.85]< 1 0% 10 studies (13/-) 99.9 % some concern low moderate crucial - deaths (time to event analysis only) 0.70 [0.40, 1.21]< 1 0% 1 study (1/-) 89.9 % NA not evaluable crucial - clinical deterioration 0.48 [0.32, 0.73]< 1 41% 4 studies (5/-) 100.0 % low not evaluable high important - clinical improvement 1.17 [0.64, 2.13]> 1 12% 2 studies (2/-) 69.3 % some concern not evaluable moderate important - clinical improvement (14-day) 2.03 [0.17, 24.32]> 1 75% 2 studies (2/-) 71.0 % some concern not evaluable moderate important - clinical improvement (7-day) 1.91 [1.03, 3.53]> 1 0% 1 study (1/-) 98.0 % NA not evaluable important - death or ventilation 0.73 [0.57, 0.93]< 1 9% 3 studies (3/-) 99.5 % some concern not evaluable moderate important - hospital discharge 1.48 [1.05, 2.09]> 1 0% 1 study (1/-) 98.6 % NA not evaluable important - hospitalization 1.00 [0.14, 7.34]< 1 0% 1 study (1/-) 50.0 % NA not evaluable important - mechanical ventilation 0.35 [0.04, 2.76]< 1 0% 2 studies (3/-) 84.1 % low not evaluable high important - radiologic improvement (14-day) 2.87 [1.56, 5.28]> 1 0% 1 study (1/-) 100.0 % NA not evaluable important - viral clearance 1.61 [0.61, 4.25]> 1 82% 3 studies (3/-) 83.1 % some concern not evaluable moderate important - viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 1 0% 1 study (1/-) 13.7 % NA not evaluable important - viral clearance by day 14 0.18 [0.00, 435.69]> 1 98% 2 studies (2/-) 34.4 % some concern not evaluable moderate important - viral clearance by day 7 2.69 [1.48, 4.87]> 1 0% 2 studies (3/-) 99.9 % some concern not evaluable moderate important - ICU admission 0.39 [0.12, 1.24]< 1 0% 2 studies (2/-) 94.5 % low not evaluable high non important - 00 serious adverse events 0.73 [0.46, 1.16]< 1 0% 4 studies (4/-) 91.0 % some concern not evaluable moderate important - adverse events 1.51 [0.91, 2.52]< 1 0% 3 studies (3/-) 5.7 % some concern not evaluable moderate non important -
LoD: level of statistical demonstration:
